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A B S T R A C T
This study was designed so as to characterize the interactions between levetiracetam (LEV) and the
conventional antiepileptic drugs (AEDs) clonazepam (CZP), ethosuximide (ETS), phenobarbital (PB), and
valproate (VPA) in suppressing pentylenetetrazole (PTZ)-induced clonic seizures inmice by use of type II
isobolographic analysis. Adverse-effect proﬁles of the drugs in combination were determined and brain
AED concentrations were measured. The combinations of VPA and ETS with LEV at the ﬁxed-ratio of 1:2,
CZP with LEV (1:20,000), and PB with LEV (1:20) were supra-additive (synergistic) in suppressing
seizures. In contrast, VPA and ETS with LEV (1:1, 2:1, and 4:1), CZP with LEV (1:1000, 1:5000, and
1:10,000), and PB with LEV (1:1, 1:5, and 1:10) were additive. No adverse effects were observed. ETS
signiﬁcantly reduced brain LEV concentrations but no other pharmacokinetic changes were observed.
The combinations of CZP with LEV (1:20,000); VPA and ETS with LEV (1:2); and PB with LEV (1:20)
appear to be favorable combinations exerting supra-additive interactions in suppressing PTZ-induced
seizures.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Approximately 70% of patients with epilepsy can be satisfactory
treatedwith amonotherapy antiepileptic drug (AED) treatment.1–3
However, for the remaining30% of patients that are refractory1,2,4
there is a need to prescribe two or more (polytherapy) AEDs in an
attempt to control their seizures.1,2 Additionally, polytherapy is
prescribed to patients who may suffer frommultiple seizure types
and usually require different AEDs in order to control their
heterogeneous seizures.5 However, AED polytherapy can be
associated with numerous problems, including acute and chronic
CNS side effects and idiosyncratic reactions, which can be
exacerbated by adverse pharmacokinetic and/or pharmacody-
namic interactions.6–8 Although there are no randomized clinical
trials to ascertain which AED combinations are most suited for a* Corresponding author at: Department of Pathophysiology, Medical University
of Lublin, Jaczewskiego 8, PL 20-090 Lublin, Poland. Tel.: +48 81 718 73 65;
fax: +48 81 718 73 64.
E-mail addresses: jluszczki@yahoo.com, jarogniew.luszczki@gmail.com
(J.J. Luszczki).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.06.009particular seizure type, anecdotal evidence and clinical experience
has highlighted some useful combinations.9 From a theoretical
point of view, the most advantageous AED combination is that
between two AEDs that are synergistic in relation to their
therapeutic (anticonvulsant) activity and thus supra-additive in
seizure suppression and with concomitant infra-additivity (antag-
onism) in relation to their adverse effects.5,10–12
Levetiracetam (LEV, [S]-alpha-ethyl-2-oxo-1-pyrrolidine acet-
amide) is a new AED that is licensed for clinical use as
monotherapy and adjunctive treatment of patients with intract-
able partial-onset seizures with or without secondary general-
ization,13–19 and for adjunctive therapy of myoclonic seizures20,21
and primary generalised tonic clonic seizures.21–23 In the clinical
setting, LEV has also been shown to be efﬁcacious in photosensitive
epilepsy,24 and in children from 4 years and older with partial-
onset seizures.25–27
In preclinical studies, it has been observed that LEV is virtually
ineffective in acute seizure models (i.e., maximal electroshock
(MES)- and pentylenetetrazole (PTZ)-induced seizures), which are
routinely used to screen for potential new AEDs.27 In contrast, LEV
increased the threshold for electroconvulsions and suppressed
seizures in kindled and genetically epileptic animals.28–33 LEV hasvier Ltd. All rights reserved.
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electrical stimulation—amodel of psychomotor seizures,34 attenu-
ates spike-and-wave discharges in DBA/2J mice (an animal model
of absence epilepsy),33 and is effective against kindled audiogenic
seizures in Krushinsky–Molodkina rats (a strain of rats selected for
susceptibility to audiogenic seizures).35 LEV produces also anti-
epileptogenic effect: it retards the acquisition of audiogenic
kindling in Krushinsky–Molodkina rats35 and inhibits the devel-
opment of hippocampal hyperexcitability following pilocarpine-
induced status epilepticus in rats.36
The precise mechanism of action of LEV has not been fully
elucidated. It reduces voltage-operated K+ current and inhibits the
delayed rectiﬁer K+ current in neurons,37 reduces N-type and
partially P/Q-type high-voltage-activated Ca2+ currents,38,39 but
not low-voltage-activated Ca2+ currents,40 suppresses the inhibi-
tory action of zinc and b-carbolines on GABAA- and glycine-gated
currents,41 blocks GABAA receptor run-down in neocortex and
thus, increases GABA-ergic inhibitory neurotransmission in the
brain,42 inhibits ryanodine receptor (RyR) and inositol 1,4,5-
triphosphate receptor (IP3R) mediated calcium-induced calcium
release (CICR) in hippocampal neurons in culture,43 and thus, LEV
by inhibiting Ca2+ release through both RyR and IP3R, affects a
major second messenger system in neurons43 and activates renal
outer medullary potassium (ROMK1) channels through a protein
kinase A (PKA)-mediated phosphorylation.44 The major physiolo-
gical function of ROMK1 channels is to maintain the resting
membrane potential during cellular excitation, therefore, LEV is
capable of reducing neuronal excitability.44 Molecular studies
involving transgenic mice suggest that LEV binds to a synaptic
vesicle protein 2A (SV2A), which is involved in vesicle neuro-
transmitter exocytosis, and that the afﬁnity of binding to SV2A
signiﬁcantly correlates with anticonvulsant potency by a series of
LEV derivatives.45
Accumulating experimental evidence indicates that LEV is
associated with favourable pharmacodynamic interaction with
numerous AEDs in various animal models including: topiramate
(TPM),10,46 oxcarbazepine (OXC), carbamazepine (CBZ),10 diaze-
pam (DZP),47 felbamate (FBM),12 gabapentin (GBP),48 valproate
(VPA) and clonazepam (CZP).49 In the case of the combination of
LEV with FBM, a synergistic interaction in terms of suppression of
MES-induced seizures was additionally complicated by a phar-
macokinetic increase in total brain LEV concentrations.12 Similarly,
the combination of LEVwith GBP, exerting a synergistic interaction
in terms of suppression of PTZ-induced clonic seizures, was
associated with a pharmacokinetic increase in total brain GBP
concentrations.48 LEV also potentiated the anticonvulsant activity
of CBZ, DZP, FBM, TPM, GBP, and VPA in sound-induced seizures in
DBA/2 mice.50 Additionally, LEV enhanced the anticonvulsant
activity of VPA, CZP, DZP, phenobarbital (PB), lamotrigine (LTG),
CBZ, vigabatrin (VGB), phenytoin (PHT), chlordiazepoxide, MK-801
(an NMDA receptor antagonist), NBQX (an AMPA/kainate receptor
antagonist), NO-711 (a GABA transporter inhibitor), allopregne-
nolone (a positive allosteric modulator of GABAA receptors),
bretazenil (a partial agonist of the benzodiazepine receptors),
propranolol (a b-adrenergic receptor blocker) and ﬂunarizine (a
calcium channel blocker) in themouse audiogenic seizuremodel.49
LEV also potentiated the anticonvulsant activity of CZP, VPA, CBZ
and PB in the rat amygdala kindlingmodel.49 Moreover, it has been
documented that LEV can pharmacodynamically potentiate the
acute neurotoxic effects of TPM and CBZ in the rotarod test in
mice.11 Clinically, a similar antiepileptic and adverse pharmaco-
dynamic interaction proﬁle has been reported in patients receiving
LEV and CBZ51 and TPM.52
Consequently, it can be considered appropriate to evaluate a
preclinical proﬁle of LEV in combination with four conventional
AEDs that are commonly used in the management of generalizedseizures namely: CZP, ethosuximide (ETS), PB, and VPA. In the
present study the anticonvulsant effects of the AED combinations
were determined in the mouse PTZ-induced clonic seizure test, a
model of myoclonic seizures in humans and the data analyzed by
use of type II isobolographic analysis.27,53 Additionally, to
determine the acute adverse-effect proﬁles for the various
combinations, the chimney test (a measure of motor performance
impairment), the step-through passive avoidance task (a measure
of long-term memory deﬁcits), and the grip-strength test (a
measure of skeletal muscular strength impairment) were used.
Finally, to ascertainwhether the observed interactionswere purely
pharmacodynamic in nature or that pharmacokinetic interactions
also contributed, brain LEV, CZP, ETS, PB and VPA concentrations
were measured.
2. Materials and methods
2.1. Animals and experimental conditions
All experiments were performed on adult male (4-week-old)
Swiss mice weighing 22–26 g. Themice were kept in colony cages
with free access to food and tap water, under standardized
housing conditions (12 h of a light–dark cycle, temperature was
21  1 8C). After 7 days of adaptation to laboratory conditions, the
animals were randomly assigned to experimental groups compris-
ing of 8 mice per group. Each mouse participated only in one
experiment and all tests were performed between 9.00 a.m. and
2.00 p.m. to minimize confounding effects of circadian rhythms.
Procedures involving animals and their care were conducted in
accordance with the European Communities Council Directive of 24
November 1986 (86/609/EEC), ‘‘Principles of laboratory animal care’’
(NIH publication No. 86-23, revised 1985), and Polish legislation on
animal experimentation. Additionally, all efforts were made to
minimize animal suffering and to use only the number of animals
necessary to produce reliable scientiﬁc data. The experimental
protocols and procedures described in this manuscript were
approved by the Local Ethics Committee at the Medical University
of Lublin (License no.: 547/2005/589/2005).
2.2. Drugs
The following AEDs were used in this study: LEV (UCB Pharma,
Braine-l’Alleud, Belgium), CZP (Polfa, Warszawa, Poland), ETS
(Sigma, St. Louis, MO, USA), PB (Polfa, Krakow, Poland) and VPA
(magnesium salt, ICN-Polfa S.A., Rzeszow, Poland). All drugs,
except for VPA, were suspended in a 1% solution of Tween 80
(Sigma, St. Louis, MO, USA) in saline, whereas VPA was directly
dissolved in saline. All drugs were administered by intraper-
itoneal (i.p.) injection in a volume of 0.005 ml/g body weight.
Fresh drug solutions were prepared on each day of experimenta-
tion and administered as follows: LEV and PB—60 min; ETS—
45 min; VPA—30 min, and CZP—15 min before PTZ administra-
tion and behavioral tests as well as before brain sampling for the
measurement of AED concentrations. These pretreatment times
were chosen based upon information about their biological
activity from the literature and our previous studies.10–12 PTZ
(Sigma, St. Louis, MO, USA) was dissolved in distilled water and
administered subcutaneously (s.c.) into a loose fold of skin in the
midline of the neck in a volume of 0.005 ml/g body weight. Since
anesthetic and/or analgesic drugs may interfere with brain
concentrations of AEDs, such drugs were not used in our study. In
order to minimize the variability of animal behavioral response
to the mild stress produced by handling and i.p. injections, each
animal was subjected to the same experimental conditions. Thus,
each mouse was given two consecutive injections of vehicle (1%
solution of Tween 80 in saline) or respective AEDs. For the
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both drugs as two separate injections; however, when one
of the mixture component drugs was tested alone, the animals
were co-administered with an equivalent amount of vehicle
as the second injection.54 Similarly, control animals were given
two consecutive injections of vehicle: the ﬁrst one at 60 min
before the testing procedure (that imitates the injection of
LEV) and the second one at the time corresponding to a
conventional AED tested. This procedure of two consecutive
vehicle injections is a principle of behavioral studies, investigat-
ing the effects of two co-injected drugs inﬂuencing the central
nervous system.54
2.3. Threshold for pentylenetetrazole-induced clonic convulsions
Clonic convulsions were induced in mice by s.c. administration
of PTZ at doses ranging between 70 and 120 mg/kg. Following PTZ
administration, mice were placed separately into transparent
Plexiglas cages (25 cm  15 cm  10 cm) and observed for 30 min
for occurrence of clonic seizures. Clonic seizure activity was
deﬁned as clonus of whole body lasting over 3 s, with an
accompanying loss of righting reﬂex. The number of animals
convulsing out of the total number of mice tested was noted for
control animals. The convulsive action of PTZ was evaluated as the
CD50 (median convulsive dose, i.e., the dose of PTZ that produced
clonic seizures in 50% of mice). To determine the CD50 value, four
doses of PTZ (50, 60, 70, and 80 mg/kg) were used (8 mice per
group) and, subsequently, an intensity–response curve was
calculated from the percentage of mice convulsing according to
the log-probit method described by Litchﬁeld and Wilcoxon.55
2.4. Pentylenetetrazole-induced clonic convulsions
The anticonvulsant activities of CZP, ETS, PB, VPA, and LEV
against the clonic phase of PTZ-induced seizures were determined
after s.c. administration of PTZ at its CD97 (convulsive dose 97, i.e.,
the dose of PTZ (98 mg/kg) that produced clonic seizures in 97% of
mice that was determined based on experiments in the vehicle-
treated mice subjected to the threshold for the PTZ-induced clonic
seizures (as described in the previous section). In order to
unequivocally assess and classify seizure activity we used a scale
for clonic seizures adapted from that described by Lo¨scher et al.53
This scale comprises of 5 stages, as follows: (1) one or more
generalized myoclonic twitches of the whole body of animals; (2)
repeated clonic seizures of fore- and hindlimbs without loss of
righting reﬂexes; (3) generalized clonic seizures lasting for over 3 s
with loss of righting reﬂexes, where the animals fall onto their side
during the generalized clonus; (4) loss of righting reﬂexes followed
by tonic forelimb seizure; and (5) loss of righting reﬂexes with
tonic fore- and hindlimb seizure.
The endpoint was that of the ﬁrst generalized clonic seizures
with loss of righting reﬂexes (stage 3) and the number of animals
convulsing out of the total number of mice tested was noted for
each treatment regimen. The animals were administered with
increasing doses of the conventional AEDs, and the anticonvulsant
activity of each drug was evaluated as the ED50 (median effective
dose of an AED, protecting 50% of mice against clonic convulsions).
At least four groups of animals were used to estimate each ED50
value calculated from the respective log-probit dose–response
relationship line according to Litchﬁeld and Wilcoxon.55 Similarly,
the anticonvulsant activity of mixtures of LEV with an AED (CZP,
ETS, PB or VPA) was evaluated and expressed as ED50 mix,
corresponding to the dose of a mixture of both drugs required
to protect 50% of animals tested against PTZ-induced clonic
convulsions. This experimental procedure has been described in
more detail in our earlier studies.482.5. Isobolographic analysis of interactions
To perform the isobolographic analysis of the interactions
between LEV and CZP, ETS, PB and VPA (as regards their
anticonvulsant activities against PTZ-induced seizures) the AEDs
in numerous ﬁxed-ratio combinations were administered to
animals. The ﬁxed drug dose ratio combinations in the type II
isobolographic analysis of interaction were selected based on the
ED50 values of the AEDs fully effective against PTZ-induced
seizures in mice. In isobolography, the selection of ﬁxed-ratio
combinations is limited also by effects evoked by a virtually
ineffective drug because the doses of LEV in the two-drug mixture
should not drastically exceed a dose of the drug that signiﬁcantly
increased the threshold for PTZ-induced seizures (200 mg/kg).
Another restriction in determination of the ﬁxed-ratio combina-
tions is the notation of the ﬁxed-ratios, which should be in the
lowest natural numbers. On the other hand, theoretically one can
select numbers of various ﬁxed-ratio combinations to precisely
determine the effect evoked by two-drug mixture. Subsequently,
the experimentally derived ED50 mix values (S.E.M.) for the
mixture were determined using log-probit analysis according to
Litchﬁeld and Wilcoxon.55 Moreover, theoretically additive ED50 add
values (S.E.M.) were calculated from the equation presented by
Porreca et al.56 and Tallarida,57 as follows: ED50 add = ED50 drug 1/P1;
where, P1 is the proportion of the ﬁrst drug, fully effective against the
clonic phase of PTZ-induced seizures (CZP, ETS, PB or VPA) in the total
amount of two-drug mixture. It should be noted that, for two-drug
mixtures the equation presented above is true when: P1 + P2 = 1;
where, P2 is the proportion of the second drug, virtually ineffective in
the PTZ test (LEV).30,32 The proportions of AEDs in the mixture are
based on a mass quantity of AEDs (for instance, a ﬁxed-ratio
combination of 1:1 comprised equal amounts of LEV and an AED).
This particular kind of type II isobolographic analysis allows the
acceptance of mass quantity of drugs in the mixture as a basis to
construct the notation of ﬁxed-ratio combinations. For instance, for
the ﬁxed-ratio of 1:2 for VPA + LEV combination, the proportion of
LEV was 2/3 = 0.6666, whilst the proportion of VPA was 1/3 = 0.3333,
in the total amount of the mixture. Subsequently, the theoretical
amount of pure additive (ED50 add) mixture at the ﬁxed-ratio of 1:2 is
calculated as follows: ED50 of VPA divided by P1. Hence,
ED50 add = 153/0.3333 = 459 mg/kg (Table 3). A more detailed
description and the theoretical background relating to isobolographic
analysis including equations showing how to calculate ED50 add
values and their S.E.M. (in the case of one investigated AED being
virtually ineffective against MES-induced seizures) has been pre-
sented in our previous studies.10,12
2.6. Measurement of total brain AED concentrations
Brain AED concentrations were determined only in mice that
were administered CZP + LEV at the ﬁxed-ratio of 1:20,000;
ETS + LEV and VPA + LEV at the ﬁxed-ratio of 1:2 as well as
PB + LEV at the ﬁxed-ratio of 1:20 from the PTZ test. These ﬁxed-
ratio combinations were chosen because they comprised of LEV
being present at maximally tested doses in this study and these
ﬁxed-ratio combinations exerted supra-additive interactions
against PTZ-induced seizures. Mice were killed by decapitation
at times chosen to coincidewith that scheduled for the PTZ test and
whole brains were removed from skulls, weighed, and homo-
genized using Abbott buffer (2:1 vol/weight; Abbott Laboratories,
North Chicago, IL, USA) in an Ultra-Turrax T8 homogenizer (IKA-
Werke, Staufen, Germany). The homogenates were centrifuged at
10,000  g for 10 min, and the supernatant samples (75ml) were
analyzed by ﬂuorescence polarization immunoassay (FPIA) for CZP,
ETS, PB, and VPA content using a TDx analyzer and reagents as
described by the manufacturer (Abbott Laboratories, North
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assay kit was used. The detection limit for benzodiazepine
concentration in the TDx analyzer was 12 ng/ml. Thus, the
analytical technique employed to quantify CZP concentrations at
a dose of 0.0114 mg/kg was not sensitive enough to detect CZP
concentrations, therefore, the drug was evaluated at a dose of
1.14 mg/kg (i.e., 100-fold higher). Total brain AED concentrations
are expressed inmg/ml (except for CZP,whose concentrationswere
expressed in ng/ml) of brain supernatants as means  S.D. of at
least 8 separate brain preparations. Brain LEV concentrations were
determined by high-performance liquid chromatography (HPLC) and
was based on the method described by Ratnaraj et al.58 The limit of
detection of the method was 0.1 mg/ml and the within-batch and
between-batch precisions were<5% and<6%, respectively. Brain LEV
concentrations are expressed in mg/ml of brain supernatants as
means  S.D. of at least 8 determinations.
2.7. Chimney test
The potential acute adverse effects of LEV and CZP, ETS, PB and
VPA on motor performance impairment were quantiﬁed with the
chimney test of Boissier et al.59 In this test, animals had to climb
backwards up a plastic tube (3 cm inner diameter, 25 cm length),
and motor impairment was indicated by the inability of the
animals to climb backward up the transparent tube within 60 s.
The animals received the combinations of LEV with CZP, ETS, PB,
and VPA at the respective ﬁxed drug dose ratios from the PTZ test
(i.e., 1:20,000 for CZP + LEV; 1:2 for ETS + LEV and VPA + LEV and
1:20 for PB + LEV). The acute adverse effects of AEDs in
combination were expressed as percentage of animals failing to
perform the chimney testwithin 60 s. This experimental procedure
has been described in more detail in our earlier studies.10,48
2.8. Step-through passive avoidance task
On the ﬁrst day before training each animal was administered
LEV,CZP,ETS,PB, andVPAeithersinglyor incombinationat thesame
ﬁxed-ratios described in the chimney test. These ﬁxed-ratio
combinations were chosen because they comprised of LEV being
present atmaximally tested doses in this study. The time before the
commencement of the training session (after drug administration)
was identical to that for the PTZ test. Subsequently, animals were
placed in an illuminatedbox (10 cm 13 cm 15 cm) connected to
a larger dark box (25 cm  20 cm 15 cm) equipped with an
electric grid ﬂoor. Entrance of animals to the dark boxwas punished
by an adequate electric footshock (0.6 mA for 2 s). The animals that
didnotenter thedarkcompartmentwereexcluded fromsubsequent
experimentation. On the following day (24 h later), the pre-trained
animalswere placed again into the illuminated box and observedup
to 180 s. Mice that avoided the dark compartment for 180 s were
considered to remember the task. The time that the mice took to
enter the dark box, was noted and the median latencies (retention
times) with 25th and 75th percentiles were calculated. The step-
through passive avoidance task gives information about ability to
acquire the task (learning) and to recall the task (retrieval).
Therefore, it may be regarded as ameasure of long-termmemory.60
This experimental procedure has been described in detail in our
earlier studies.10,48
2.9. Grip-strength test
The effects of the various AEDs, administered singly or in
combination at the ﬁxed-ratios described for the chimney test, on
skeletal muscular strength in mice were quantiﬁed by the grip-
strength test of Meyer et al.61 These ﬁxed-ratio combinations were
chosen because they comprised of LEV being present at maximallytested doses. The time before the commencement of the grip-
strength test (after AED administration) was identical to that for
the PTZ test. The grip-strength apparatus (BioSeb, Chaville, France)
comprised a wire grid (8 cm  8 cm) connected to an isometric
force transducer (dynamometer). The mice were lifted by the tail
so that their forepaws could grasp the grid. The mice were then
gently pulled backward by the tail until the grid was released. The
maximal force exerted by the mouse before losing grip was
recorded. The mean of three measurements for each animal was
calculated and subsequently, the meanmaximal force of 8 animals
per group was determined. The grip-strength test was used to
determine the effects of AEDs on skeletalmuscular strength, which
was expressed in newton (N) as means  S.D. of at least 8
determinations (3 measurements for each of 8 animals per group).
This experimental procedure has been described inmore detail in our
earlier study.48
2.10. Statistics
The CD50 and ED50 values with their 95% conﬁdence limits were
calculated by computer-assisted log-probit analysis according to
Litchﬁeld and Wilcoxon.55 The obtained 95% conﬁdence limits
were transformed to S.E.M. as described previously.10 Statistical
evaluation of isobolographic interactions was performed by the
use of Student’s t-test in order to detect the differences between
the experimentally derived (ED50 mix) and theoretical additive
(ED50 add) values, according to Porreca et al.
56 and Tallarida.57 Total
brain AED concentrations were statistically analyzed using the
unpaired Student’s t-test. The results from the step-through
passive avoidance task were statistically analyzed using Kruskal–
Wallis nonparametric ANOVA test. The data from the grip-strength
test were statistically analyzed using one-way ANOVA. Qualitative
variables from the chimney test were compared by use of the
Fisher’s exact probability test. Results were considered statistically
signiﬁcant if P < 0.05.
3. Results
3.1. Threshold for PTZ-induced clonic seizures
In control (vehicle-treated) animals, the dose–response effect
allowed the determination of an equation from which both CD50
and CD97 values were calculated. The PTZ CD97 value reﬂects the
dose of PTZ that is required to evoke clonic seizures in 97% of
animals tested and this value was determined to be 98 mg/kg
(result not shown).
3.2. Anticonvulsant effects of LEV and conventional AEDs against PTZ-
induced seizures
LEV administered systemically (i.p., 60 min before the test) at
doses of 50, 100 and 200 mg/kg did not protect any animals against
the clonic phase of PTZ-induced seizures (Table 1). In contrast, LEV
at the higher doses of 300 and 400 mg/kg protected 12.5% of
animals tested, whereas LEV at 500 mg/kg protected 37.5% of
animals tested. All the conventional AEDs (CZP, ETS, PB, and VPA)
administered alone exhibited a clear-cut anticonvulsant activity in
the mouse PTZ test and their ED50 values are shown in Table 2.
3.3. Isobolographic analysis of interactions between LEV and CZP, ETS,
PB and VPA against PTZ-induced clonic convulsions
Isobolographic analysis revealed that the combination of CZP
with LEV at the ﬁxed-ratio of 1:20,000 was supra-additive
(synergistic) in the PTZ test (P < 0.05; Table 3; Fig. 1A). In contrast,
the AED combinations at ﬁxed-ratios of 1:1000, 1:5000 and
Table 1
Anticonvulsant effect of levetiracetam (LEV) against pentylenetetrazole (PTZ)-
induced clonic seizures.





LEV (50) 0/8 0
LEV (100) 0/8 0
LEV (200) 1/8 12.5
LEV (300) 1/8 12.5
LEV (400) 1/8 12.5
LEV (500) 3/8 37.5
Each group comprised of 8 animals and LEVwas administered i.p. at 60 min prior to
the PTZ test. Clonic convulsions were evoked by the s.c. administration of PTZ at the
dose of CD97 (98 mg/kg).
Table 2
The anticonvulsant activity of various antiepileptic drugs against pentylenete-
trazole (PTZ)-induced clonic seizures.
Drug ED50 (mg/kg) n
CZP 0.023  0.008 8
ETS 132.4  9.353 32
PB 13.9  0.856 24
VPA 153.0  9.913 16
Results are presented as median effective doses (ED50  S.E.M.) protecting 50% of
animals tested against PTZ-induced convulsions. n—total number of animals tested at
those doses whose expected anticonvulsant effects ranged between 16% and 84%,
according to Litchﬁeld and Wilcoxon.55 The AEDs were administered i.p., phenobarbi-
tal (PB)—60 min; ethosuximide (ETS)—45 min; valproate (VPA)—30 min, and clona-
zepam (CZP)—15 min, prior to the PTZ test. Clonic convulsions were evoked by the s.c.
administration of PTZ at the dose of CD97 (98 mg/kg).
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pattern was observed for the combination of ETS with LEV. It was
documented that the AEDs in combination at the ﬁxed-ratio of 1:2
exerted supra-additive interaction in suppressing PTZ-induced
clonic seizures (P < 0.05; Table 3; Fig. 1B). The remaining
combinations between ETS and LEV (i.e., at the ﬁxed-ratios of
1:1, 2:1 and 4:1) showed additive interaction (Table 3; Fig. 1B). The
combination comprising of PB and LEV was associated with supra-
additivity for the ﬁxed-ratio of 1:20 (P < 0.05; Table 3; Fig. 1C). The
remaining AED combinations at ﬁxed-ratios of 1:1, 1:5 and 1:10Table 3
Isobolographic characterization of interactions between levetiracetam (LEV) and variou
AED combination FR AED LEV ED50 mix (mg/
CZP + LEV 1:1000 0.018 18.36 18.38  5.739
CZP + LEV 1:5000 0.018 91.82 91.84  28.67
CZP + LEV 1:10,000 0.0135 135.1 135.1  36.92
CZP + LEV 1:20,000 0.0114 227.7 227.7  24.57
ETS + LEV 4:1 114.0 28.5 142.5  10.08
ETS + LEV 2:1 105.3 52.7 158.0  11.36
ETS + LEV 1:1 104.0 104.0 208.0  22.52
ETS + LEV 1:2 97.4 194.9 292.3  28.40
PB + LEV 1:1 12.1 12.1 24.2  3.14
PB + LEV 1:5 11.7 58.2 69.9  7.63
PB + LEV 1:10 11.5 114.8 126.3  11.71
PB + LEV 1:20 10.9 217.8 228.7  24.91
VPA + LEV 4:1 140.4 35.1 175.5  12.73
VPA + LEV 2:1 140.1 70.1 210.2  16.38
VPA + LEV 1:1 126.0 126.0 252.0  20.03
VPA + LEV 1:2 104.2 208.5 312.7  38.14
Data are presented as median effective doses (ED50  S.E.M.) protecting 50% of animals te
from themixture of two AEDs (ED50 mix) or theoretically calculated from the equation of addi
Student’s t-test. PTZ was administered s.c. at a dose of 98 mg/kg, being its CD97 value. FR—ﬁx
number of animals at those doses whose expected anticonvulsant effects ranged between 4
calculated ðn0addÞ from the equation of additivity; CZP—clonazepam, ETS—ethosuximide, PB
* P < 0.05 vs. the respective ED50 add, indicating supra-additive (synergistic) interacti
** P < 0.01 vs. the respective ED50 add, indicating supra-additive (synergistic) interactwere additive (Table 3; Fig. 1C). Similarly, the combination of VPA
with LEV at the ﬁxed-ratio of 1:2 was supra-additive (P < 0.01;
Table 3; Fig. 1D), whereas the other ﬁxed-ratio combinations of
1:1, 2:1, and 4:1 were additive (Table 3; Fig. 1D).
3.4. Effects of LEV administered alone and in combinations with CZP,
ETS, PB and VPA on long-term memory, motor performance and
skeletal muscular strength
None of the studied combinations of LEV with CZP, ETS, PB and
VPA impaired long-term memory as determined in the passive
avoidance task (Table 4). Similarly, these combinations had no
effect on skeletal muscular strength, as assessed by the grip-
strength test (Table 4), and did not alter motor performance in
animals challengedwith the chimney test (Table 4). Moreover, LEV
administered alone at a dose of 200 mg/kg did not affect long-term
memory, motor performance and skeletal muscular strength
(Table 4).
3.5. Brain AED concentrations
Total brain concentrations of CZP, ETS, PB and VPA did not differ
signiﬁcantly from those determined when these AEDs were
administered in combination with LEV (co-administered at the
ﬁxed-ratios of 1:20,000 for CZP + LEV; 1:2 for VPA + LEV and
ETS + LEV; 1:20 for PB + LEV from the PTZ test) (Table 5).
Whilst total brain LEV concentrations were not signiﬁcantly
different when LEV was administered in combination with CZP, PB
and VPA as compared to when LEV was administered alone,
concentrations were signiﬁcantly decreased (14%; P < 0.01) when
LEV was administered in combination with ETS (Table 6).
4. Discussion
In contrast to other AEDs, LEV is virtually ineffective in acute
seizure models (MES- and PTZ-induced seizures), which are
routinely used to screen for potential new AEDs and consequently
its anticonvulsant effects were nearly overlooked.27 In the present
studywe similarly observed aminimal anticonvulsant effect of LEV
in themouse PTZmodel in that it was without effect at 50, 100 and
200 mg/kg but protected 12.5% of animals administered 300 and
400 mg/kg LEV and 37.5% of animals administered 500 mg/kg LEVs AEDs in the mouse pentylenetetrazole (PTZ)-induced seizure model.
kg) n0mix ED50 add (mg/kg) n0add AED LEV
16 23.023  8.168 6 0.023 23.0
16 115.023  40.81 6 0.023 115.0
16 230.023  81.61 6 0.023 230.0
* 24 460.023  163.22 6 0.023 460.0
32 165.5  11.69 30 132.4 33.1
16 198.6  14.03 30 132.4 66.2
24 264.8  18.71 30 132.4 132.4
* 16 397.2  28.06 30 132.4 264.8
40 27.8  1.71 22 13.9 13.9
24 83.4  5.14 22 13.9 69.5
24 152.9  9.42 22 13.9 139.0
* 16 291.9  17.98 22 13.9 278.0
24 191.3  12.39 14 153.0 38.3
24 229.5  14.87 14 153.0 76.5
16 306.0  19.83 14 153.0 153.0
** 24 459.0  29.74 14 153.0 306.0
sted against PTZ-induced seizures. ED50 values were either experimentally determined
tivity (ED50 add). Statistical evaluation of the data was performed by use of the unpaired
ed-ratio of drug dose combinations; LEV, AED—doses of AEDs in the mixtures; n0—total




Fig. 1. (A–D) Isobologram showing interactions between levetiracetam (LEV) and various antiepileptic drugs (AEDs) against pentylenetetrazole (PTZ)-induced clonic seizures.
LEV doses are plotted graphically on the X-axis, whereas the doses of clonazepam (CZP), ethosuximide (ETS), phenobarbital (PB) and valproate (VPA) are plotted on the Y-axis.
The heavy line is parallel to the X-axis, representing the ED50 value for the AEDs administered alone, and deﬁnes the theoretical dose-additive line for a continuum of different
ﬁxed dose ratios. The dotted lines represent 95% conﬁdence limits for conventional AEDs administered alone. The closed circles (*) depict the experimentally derived
ED50 mix values for total doses of mixtures expressed as proportions of LEV and an AED that produced median anticonvulsant effects. Since 95% conﬁdence limits for ED50 mix
values could be readily transformed to S.E.M. and, inversely, S.E.M. to 95% conﬁdence limits, the 95% conﬁdence limits represent an actual calculation of the vertical and
horizontal component of the error. (A) Interactions between CZP and LEV. The experimental ED50 mix for themixture of CZP + LEV at the ﬁxed-ratios of 1:20,000 is signiﬁcantly
below the theoretical line of additivity, indicating supra-additivity (*P < 0.05). The other ﬁxed-ratios of 1:1000, 1:5000 and 1:10,000 are close to the line of additivity,
indicating additive interaction. (B) Interactions between ETS and LEV. The experimental ED50 mix of the mixture of ETS + LEV for the ﬁxed-ratio of 1:2 is placed signiﬁcantly
below the line of additivity, indicating supra-additivity (*P < 0.05). All the remaining ﬁxed-ratios tested (4:1, 2:1 and 1:1) are close to the line of additivity, indicating additive
interaction. (C) Interactions between PB and LEV. The experimental ED50 mix for the ﬁxed-ratio of 1:20 is plotted signiﬁcantly below the line of additivity, indicating supra-
additivity (*P < 0.05). The other ﬁxed-ratio combinations of 1:1, 1:5 and 1:10) are close to the line of additivity and thus displaying additive interaction. (D) Interactions
between VPA and LEV. The experimental ED50 mix of the mixture of VPA + LEV for the ﬁxed-ratio of 1:2 is placed signiﬁcantly below the line of additivity, indicating supra-
additivity (**P < 0.01). The other ﬁxed-ratios tested (4:1, 2:1 and 1:1) are plotted near the line of additivity, indicating additive interaction.
Table 4
Effect of levetiracetam (LEV) administered singly or in combinationwith various antiepileptic drugs (AEDs) onmotor coordination, long-termmemory andmuscular strength
in the chimney test, step-through passive avoidance task and grip-strength test.
Treatment (mg/kg) FR Motor impairment (%) Retention time (s) Grip-strength (N)
Vehicle – 0 180 (180–180) 102.5  12.3
LEV (200) + vehicle – 0 180 (175–180) 103.5  11.9
CZP (0.0114) + LEV (228) 1:20,000 0 180 (165.5–180) 100.5  12.1
ETS (97.4) + LEV (195) 1:2 12.5 180 (135–180) 101.5  12.8
PB (10.9) + LEV (218) 1:20 0 180 (165–180) 108.5  13.0
VPA (104) + LEV (209) 1:2 12.5 177.5 (153.5–180) 99.5  11.8
Results are presented as follows: (1) the percentage of motor coordination impairment in mice subjected to the chimney test; (2) median retention times (in seconds with
25th and 75th percentiles in parentheses) of animals in the step-through passive avoidance task; (3) mean muscular strength (in newtons [N]  S.D. of 8 determinations) in
animals subjected to the grip-strength test. The AEDs were administered i.p.: LEV, phenobarbital (PB)—60 min, ethosuximide (ETS)—45 min, valproate (VPA)—30 min, and
clonazepam (CZP)—15 min, prior to the tests. Results from the chimney test were evaluated statistically by use of the Fisher’s exact probability test. Data from the step-trough
passive avoidance task were statistically assessed by use of the Kruskal–Wallis nonparametric ANOVA test, whereas the results from the grip-strength test were analyzed by use of
the one-way ANOVA.
M. Dudra-Jastrzebska et al. / Seizure 18 (2009) 607–614612(Table 1). This apparent plateau effect of efﬁcacy versus dose for
LEV is in agreement with that reported earlier by Lo¨scher and
Ho¨nack32 and Klitgaard et al.30 Because of this characteristic it was
not possible to determine the ED50 value for LEV against PTZ-
induced seizures.
The isobolographic analysis clearly shows that LEV synergis-
tically interacts with all tested AEDs in the PTZ test, however, only
at those ﬁxed-ratio combinations in which doses of LEV in the
mixture were close to or higher than 200 mg/kg attained statistical
signiﬁcance. Thus, it can be concluded that whilst at doses lower
than 200 mg/kg the interaction of LEV with the other AEDs isprobably purely synergistic in nature, that at doses greater than
200 mg/kg are probably only additive in nature. Such a conclusion
would be in line with previous published data whereby synergism
was observed between LEV and TPM and FBM in the MES test in
which LEV was present at doses lower than 150 mg/kg10,12 and
between LEV and CBZ and OXC in which LEV was present at doses
ranging between 70 and 125 mg/kg.10
With regards to impairment of motor performance (as assessed
by the chimney test), it was observed that LEV in combination with
all testedAEDs at doses from the PTZ test producedno acute adverse
effects. Similarly, the combinations of LEV with conventional AEDs
Table 5
Total brain concentrations of the various antiepileptic drugs when administered
singly or in combination with levetiracetam (LEV).
Treatment (mg/kg) Brain concentrations (mg/ml) (ng/ml)
CZP (1.14) + vehicle 30.76  0.50
CZP (1.14) + LEV (228) 31.09  0.46
ETS (97.4) + vehicle 11.12  1.66
ETS (97.4) + LEV (195) 12.07  1.58
PB (10.9) + vehicle 6.14  0.47
PB (10.9) + LEV (218) 6.41  0.55
VPA (104) + vehicle 50.85  10.75
VPA (104) + LEV (209) 59.88  12.49
Data are presented asmeans (S.D.) of at least 8 determinations. Statistical evaluation
of data was performed by the use of the unpaired Student’s t-test. Brain tissue samples
were taken at times scheduled for the PTZ test. Because the analytical technique
employed to quantify CZP concentrations at a dose of 0.0114 mg/kg, was not sensitive
enough (see Section 2), the drug was evaluated at a dose of 1.14 mg/kg (i.e., 100-fold
higher). CZP—clonazepam, ETS—ethosuximide, PB—phenobarbital, VPA—valproate.
Table 6
Total levetiracetam (LEV) brain concentrations when administered singly or in
combination with various antiepileptic drugs.
Treatment (mg/kg) Brain concentrations (mg/ml)
LEV (195) + vehicle 36.88  3.33
LEV (195) + ETS (97.4) 31.62  1.87**
LEV (209) + vehicle 31.90  3.78
LEV (209) + VPA (104) 32.26  4.95
LEV (218) + vehicle 28.94  2.67
LEV (218) + PB (10.9) 26.70  2.96
LEV (228) + vehicle 30.17  3.77
LEV (228) + CZP (0.0114) 31.96  2.19
Results are presented asmeans  S.D. of at least 8 determinants. Statistical evaluation
of data was performed by use of the unpaired Student’s t-test. CZP—clonazepam; ETS—
ethosuximide, PB—phenobarbital; VPA—valproate.
** P < 0.01 vs. the respective control (LEV + vehicle-treated) animals.
M. Dudra-Jastrzebska et al. / Seizure 18 (2009) 607–614 613altered neither long-term memory in mice challenged with the
passive avoidance task, nor skeletal muscular strength in animals
subjected to the grip-strength test.
Interestinglywepreviously observed LEVbrain concentrations
to increase dose-proportionately over the dose range of 5.6–
267 mg/kg.10,12 In the present study dose-proportionality over
the dose range of 195–228 was not observed although the
concentrations observed were of the order expected. A possible
explanation for this is that a plateau effect occurred over this
rather narrowdose range (Table 5). Total LEVbrain concentrations
were signiﬁcantly decreased by ETS, whereas CZP, PB and VPA had
no signiﬁcant effect. Furthermore, LEV co-administration had no
signiﬁcant effect on CZP, ETS, PB and VPA total brain concentra-
tions. Overall, therefore, the observed isobolographic interactions
canbe considered tobe pharmacodynamic innature.With regards
to the combination of CZP with LEV, the brain concentrations of
CZP were determined after 1.14 mg/kg CZP administration (i.e.,
100-fold higher than that denoted experimentally) because the
assaywas by an immunoﬂuorescence technique,whichwas out of
the detecting range of CZP when administered at a dose
0.0114 mg/kg.
An important pharmacokinetic characteristic of LEV is that it is
not metabolized in the liver (primarily excreted unchanged via the
kidneys) and is not bound to blood albumin and consequently its
propensity to interact with other AEDs is minimal and indeed this
iswhat is observed clinically.6–8,62 In the study by Kaminski et al.,49
however, LEV signiﬁcantly reduced plasma and brain concentra-
tions of VPA, but was without effect on PB, PHT and CBZ
concentrations. In contrast, in the present study, we did not
observe an effect by LEV on VPA brain concentrations (Table 5). The
observed difference between the two studies in this regard may be
attributable to the strain of animals used (Albino Swiss mice vs.audiogenic susceptible mice) although theoretically there should
not be any pharmacokinetic interaction between the two AEDs.
Finally, and also unexpectedly ETS lowered LEV brain concentra-
tions (Table 6) and perhaps this too could be explained in part by
species differences.
In conclusion, the present study indicates that LEV in
combination with ETS, CZP, PB and VPA offers potential antic-
onvulsant synergy in the PTZ-induced seizure model without
concurrent acute adverse effects and consequently may be the
basis of further study in the clinical setting since. The pharma-
codynamic interaction between ETS and LEV was associated with
concurrent lower LEV brain concentrations, an effect thatmay have
served to underestimate the interaction.
Acknowledgements
The authors are grateful for the generous gift of valproate
magnesium from ICN Polfa S.A. (Rzeszow, Poland) and levetir-
acetam from UCB Pharma (Braine-l’Alleud, Belgium). This study
was supported by a grant from Institute of Agricultural Medicine
(Lublin, Poland).
References
1. Kwan P, Brodie MJ. Early identiﬁcation of refractory epilepsy. New England
Journal of Medicine 2000;342:314–9.
2. Kwan P, Brodie MJ. Epilepsy after the ﬁrst drug fails: substitution or add-on?
Seizure 2000;9:464–8.
3. Reynolds EH, Shorvon SD. Single drug or combination therapy for epilepsy?
Drugs 1981;21:374–82.
4. Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, et al.
Selection of antiepileptic drug polytherapy based on mechanism of action: the
evidence reviewed. Epilepsia 2000;41:1364–74.
5. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neuro-
logica Scandinavica 1995;(Suppl. 162):31–4.
6. Patsalos PN, Fro¨scher W, Pisani F, van Rijn CM. The importance of drug
interactions in epilepsy therapy. Epilepsia 2002;43:365–85.
7. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy:
general features and interactions between antiepileptic drugs. Lancet Neurol-
ogy 2003;2:347–56.
8. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy:
interactions between antiepileptic drugs and other drugs. Lancet Neurology
2003;2:473–81.
9. Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug.
Seizure 2002;11:349–51.
10. Luszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Ratnaraj N, Patsalos
PN, et al. Pharmacodynamic and pharmacokinetic characterization of interac-
tions between levetiracetam and numerous antiepileptic drugs in the mouse
maximal electroshock seizure model: an isobolographic analysis. Epilepsia
2006;47:10–20.
11. Luszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Wojcik-Cwikla J,
Ratnaraj N, et al. Levetiracetam selectively potentiates the acute neurotoxic
effects of topiramate and carbamazepine in the rotarod test in mice. European
Neuropsychopharmacology 2005;15:609–16.
12. Luszczki JJ, Andres-Mach MM, Ratnaraj N, Patsalos PN, Czuczwar SJ. Levetir-
acetam and felbamate interact both pharmacodynamically and pharmacoki-
netically: an isobolographic analysis in the mouse maximal electroshock
model. Epilepsia 2007;48:806–15.
13. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U. Levetiracetam
N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic
generalized epilepsy. Neurology 2007;69:1751–60.
14. Alsaadi TM, Shatzel A, Marquez AV, Jorgensen J, Farias S. Clinical experience of
levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study.
Seizure 2005;14:139–42.
15. Ben-MenachemE, Falter U. Efﬁcacy and tolerability of levetiracetam 3000 mg/d
in patients with refractory partial seizures: a multicenter, double-blind,
responder-selected study evaluating monotherapy. European Levetiracetam
Study Group. Epilepsia 2000;41:1276–83.
16. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam
for partial seizures: results of a double-blind, randomized clinical trial. Neu-
rology 2000;55:236–42.
17. Grant R, Shorvon SD. Efﬁcacy and tolerability of 1000–4000 mg per day of
levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy
Research 2000;42:89–95.
18. Khurana DS, Kothare SV, Valencia I, Melvin JJ, Legido A. Levetiracetam mono-
therapy in children with epilepsy. Pediatric Neurology 2007;36:227–30.
19. Sharief MK, Singh P, Sander JWAS, Patsalos PN, Shorvon SD. Efﬁcacy and
tolerability study of ucb L059 in patients with refractory epilepsy. Journal of
Epilepsy 1996;9:106–12.
M. Dudra-Jastrzebska et al. / Seizure 18 (2009) 607–61461420. Greenhill L, Betts T, Smith K. Effect of levetiracetam on resistant juvenile
myoclonic epilepsy. Epilepsia 2001;42(Suppl. 7):179 [abstract].
21. Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalised epilepsies.
Seizure 2004;13:475–7.
22. Specchio LM, Gambardella A, Giallonardo AT,Michelucci R, Specchio N, Boero G,
et al. Open label, long-term, pragmatic study on levetiracetam in the treatment
of juvenile myoclonic epilepsy. Epilepsy Research 2006;71:32–9.
23. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disorders
2000;2:112–209.
24. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J.
Photosensitive epilepsy: a model to study the effects of antiepileptic drugs.
Evaluation of the piracetam analogue, levetiracetam. Epilepsy Research
1996;25:225–30.
25. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al.
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric
partial seizures. Neurology 2006;66:1654–60.
26. Tan MJ, Appleton RE. Efﬁcacy and tolerability of levetiracetam in children aged
10 years and younger: a clinical experience. Seizure 2004;13:142–5.
27. Lo¨scher W, Schmidt D. Which animal models should be used in the search for
new antiepileptic drugs? A proposal based on experimental and clinical
considerations. Epilepsy Research 1988;2:145–81.
28. Gower AJ, Hirsch E, Boehrer A, NoyerM,Marescaux C. Effects of levetiracetam, a
novel antiepileptic drug, on convulsant activity in two genetic rat models of
epilepsy. Epilepsy Research 1995;22:207–13.
29. Gower AJ, Noyer M, Verloes R, Gobert J, Wulfert E. Ucb L059 a novel anti-
convulsant drug: pharmacological proﬁle in animals. European Journal of
Pharmacology 1992;222:193–203 [erratum published in: European Journal of
Pharmacology 1993;230:389].
30. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique proﬁle of
levetiracetam in rodent models of seizures and epilepsy. European Journal of
Pharmacology 1998;353:191–206.
31. Lo¨scher W, Ho¨nack D, Rundfeldt C. Antiepileptogenic effects of the novel
anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal
lobe epilepsy. Journal of Pharmacology and Experimental Therapeutics
1998;284:474–9.
32. Lo¨scher W, Ho¨nack D. Proﬁle of ucb L059, a novel anticonvulsant drug, in
models of partial and generalized epilepsy inmice and rats. European Journal of
Pharmacology 1993;232:147–58.
33. Marrosu F, BortolatoM, Frau R, OrruM, PulighedduM, FaM, et al. Levetiracetam
attenuates spontaneous spike-and-wave discharges in DBA/2J mice. Epilepsy
Research 2007;75:224–7.
34. Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of
the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Research
2001;47:217–27.
35. Vinogradova LV, van Rijn CM. Anticonvulsive and antiepileptogenic effects of
levetiracetam in the audiogenic kindling model. Epilepsia 2008;49:1160–8.
36. Margineanu DG, Matagne A, Kaminski RM, Klitgaard H. Effects of chronic
treatment with levetiracetam on hippocampal ﬁeld responses after pilocar-
pine-induced status epilepticus in rats. Brain Research Bulletin 2008;77:282–5.
37. Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, et al.
Reduction of voltage-operated potassium currents by levetiracetam: a novel
antiepileptic mechanism of action? Neuropharmacology 2003;45:661–71.
38. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium
channels by levetiracetam. Epilepsia 2002;43:9–18.
39. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-
voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal
slices. Neuroscience Letters 2001;306:5–8.
40. Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG.
Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+
currents. Seizure 2001;10:279–86.
41. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, et al. The anti-
epileptic drug levetiracetam reverses the inhibition by negative allosteric
modulators of neuronal GABA- and glycine-gated currents. British Journal of
Pharmacology 2002;136:659–72.
42. Palma E, Roseti C, Maiolino F, Fucile S, Martinello K, Mazzuferi M, et al.
GABA(A)-current rundown of temporal lobe epilepsy is associated with repe-titive activation of GABA(A) ‘‘phasic’’ receptors. Proceedings of the National
Academy of Sciences of the United States of America 2007;104:20944–8.
43. Nagarkatti N, Deshpande LS, DeLorenzo RJ. Levetiracetam inhibits both ryano-
dine and IP3 receptor activated calcium induced calcium release in hippocam-
pal neurons in culture. Neuroscience Letters 2008;436:289–93.
44. Lee CH, Lee CY, Tsai TS, Liou HH. PKA-mediated phosphorylation is a novel
mechanism for levetiracetam, an antiepileptic drug, activating ROMK1 chan-
nels. Biochemical Pharmacology 2008;76:225–35.
45. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A,
et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic
drug levetiracetam. Proceedings of the National Academy of Sciences of the
United States of America 2004;101:9861–6.
46. Sills GJ, Butler E, Thompson GG, Brodie MJ. Pharmacodynamic interaction
studies with topiramate in the pentylenetetrazol and maximal electroshock
seizure models. Seizure 2004;13:287–95.
47. Mazarati AM, Baldwin R, Klitgaard H, Matagne A, Wasterlain CG. Anticonvul-
sant effects of levetiracetam and levetiracetam–diazepam combinations in
experimental status epilepticus. Epilepsy Research 2004;58:167–74.
48. Dudra-Jastrzebska M, Andres-Mach MM, Sielski M, Ratnaraj N, Patsalos PN,
Czuczwar SJ, et al. Pharmacodynamic and pharmacokinetic interaction proﬁles
of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in
the mouse pentylenetetrazole-induced seizure model: an isobolographic ana-
lysis. European Journal of Pharmacology 2009;605:87–94.
49. Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Beneﬁts of combination
therapy in epilepsy: a review of preclinical evidence with levetiracetam.
Epilepsia 2009;50:387–97.
50. Donato Di Paola E, Gareri P, Davoli A, Gratteri S, Scicchitano F, Naccari C, et al.
Inﬂuence of levetiracetam on the anticonvulsant efﬁcacy of conventional
antiepileptic drugs against audiogenic seizures in DBA/2 mice. Epilepsy
Research 2007;75:112–21.
51. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combina-
tion therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy
Research 2002;48:217–9.
52. Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CM, et al.
Efﬁcacy and safety of levetiracetam in children with partial seizures: an open-
label trial. Epilepsia 2002;43:518–24.
53. Lo¨scher W, Ho¨nack D, Fassbender CP, Nolting B. The role of technical, biological
andpharmacological factors in the laboratory evaluationof anticonvulsantdrugs.
III. Pentylenetetrazole seizure models. Epilepsy Research 1991;8:171–89.
54. Lapin IP. Only controls: effect of handling, sham injection, and intraperitoneal
injection of saline on behavior of mice in an elevated plus-maze. Journal of
Pharmacological and Toxicological Methods 1995;34:73–7.
55. Litchﬁeld JT, Wilcoxon F. A simpliﬁed method of evaluating dose-effect
experiments. Journal of Pharmacology and Experimental Therapeutics
1949;96:99–113.
56. Porreca F, Jiang Q, Tallarida RJ. Modulation of morphine antinociception by
peripheral [Leu5]enkephalin: a synergistic interaction. European Journal of
Pharmacology 1990;179:463–8.
57. Tallarida RJ. Drug synergism and dose-effect data analysis. Boca Raton, FL:
Chapman & Hall/CRC; 2000.
58. Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of
the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by
high performance liquid chromatography. Therapeutic Drug Monitoring
1996;18:154–7.
59. Boissier JR, Tardy J, Diverres JC. Une nouvelle me´thode simple pour explorer
l’action tranquilisante: le test de la chemine´e. Medicina Experimentalis (Basel)
1960;3:81–4.
60. Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, et al.
Benzodiazepines impair and beta-carbolines enhance performance in learning
and memory tasks. Nature 1986;321:864–6.
61. Meyer OA, Tilson HA, Byrd WC, Riley MT. A method for the routine assessment
of fore- and hindlimb grip strength of rats and mice. Neurobehavioral Toxicol-
ogy 1979;1:233–6.
62. Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of
epilepsy and other neurological conditions. Reviews in Contemporary Pharma-
cotherapy 2004;13:1–168.
